Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
LGVN Longeveron	$1.32 +1.5%	$1.38	$1.14 ▼ $6.40	$19.71M	0.22	1.38 million shs	184,661 shs
LMDX LumiraDx		$0.01	$0.02 ▼ $1.33	$5.10M	1.73	56.75 million shs	132.24 million shs
OVID Ovid Therapeutics	$0.30 -12.0%	$0.30	$0.24 ▼ $1.47	$21.48M	0.08	433,773 shs	8.88 million shs
RNXT RenovoRx	$1.28 -5.2%	$1.21	$0.75 ▼ $1.69	$46.81M	1.32	98,102 shs	243,724 shs

Elon Musk's Next Move

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
LGVN Longeveron	0.00%	+10.00%	+6.45%	-14.84%	-18.01%
LMDX LumiraDx	0.00%	0.00%	0.00%	0.00%	0.00%
OVID Ovid Therapeutics	0.00%	-2.71%	+7.86%	-3.17%	-60.74%
RNXT RenovoRx	0.00%	-7.25%	-5.54%	+29.29%	+13.27%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
LGVN Longeveron	3.713 of 5 stars	3.6	5.0	0.0	0.0	2.7	1.7	1.3
LMDX LumiraDx	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OVID Ovid Therapeutics	4.5549 of 5 stars	3.6	3.0	0.0	4.6	3.1	2.5	0.6
RNXT RenovoRx	3.0339 of 5 stars	3.5	5.0	0.0	0.0	2.7	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
LGVN Longeveron	3.25	Buy	$8.67	556.57% Upside
LMDX LumiraDx	0.00	N/A	N/A	N/A
OVID Ovid Therapeutics	3.20	Buy	$3.13	934.77% Upside
RNXT RenovoRx	3.00	Buy	$7.25	466.41% Upside

Current Analyst Ratings Breakdown

Latest LMDX, RNXT, LGVN, and OVID Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/5/2025	RNXT RenovoRx	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$11.00 ➝ $11.50
5/27/2025	OVID Ovid Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$2.00 ➝ $1.50
5/19/2025	RNXT RenovoRx	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00 ➝ $3.00
4/28/2025	RNXT RenovoRx	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$9.00 ➝ $11.00
4/24/2025	OVID Ovid Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
4/4/2025	RNXT RenovoRx	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.00 ➝ $3.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
LGVN Longeveron	$2.39M	8.25	N/A	N/A	$1.47 per share	0.90
LMDX LumiraDx	$126.52M	0.00	N/A	N/A	($0.33) per share	0.00
OVID Ovid Therapeutics	$570K	37.68	N/A	N/A	$0.96 per share	0.31
RNXT RenovoRx	$40K	1,170.24	N/A	N/A	$0.19 per share	6.74

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
LGVN Longeveron	-$15.97M	-$6.28	N/A	N/A	N/A	-760.72%	-85.07%	-70.74%	8/13/2025 (Estimated)
LMDX LumiraDx	-$447.79M	-$1.09	N/A	N/A	N/A	-268.45%	N/A	-77.91%	N/A
OVID Ovid Therapeutics	-$26.43M	-$0.35	N/A	N/A	N/A	-4,562.23%	-34.17%	-25.34%	8/12/2025 (Estimated)
RNXT RenovoRx	-$8.81M	-$0.40	N/A	N/A	N/A	N/A	-119.58%	-88.01%	8/12/2025 (Estimated)

Latest LMDX, RNXT, LGVN, and OVID Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	RNXT RenovoRx	-$0.08	-$0.08	N/A	-$0.08	$0.23 million	$0.20 million
5/13/2025	Q1 2025	OVID Ovid Therapeutics	-$0.14	-$0.14	N/A	-$0.14	$0.03 million	$0.13 million
3/31/2025	Q4 2024	RNXT RenovoRx	-$0.12	-$0.13	-$0.01	-$0.12	$0.17 million	$0.04 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
LGVN Longeveron	N/A	N/A	N/A	N/A	N/A
LMDX LumiraDx	N/A	N/A	N/A	N/A	N/A
OVID Ovid Therapeutics	N/A	N/A	N/A	N/A	N/A
RNXT RenovoRx	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
LGVN Longeveron	N/A	5.61	5.61
LMDX LumiraDx	N/A	0.45	0.23
OVID Ovid Therapeutics	0.22	4.93	4.93
RNXT RenovoRx	N/A	9.07	9.07

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
LGVN Longeveron	10.01%
LMDX LumiraDx	9.59%
OVID Ovid Therapeutics	72.24%
RNXT RenovoRx	3.10%

Insider Ownership

Company	Insider Ownership
LGVN Longeveron	11.20%
LMDX LumiraDx	35.41%
OVID Ovid Therapeutics	13.10%
RNXT RenovoRx	9.13%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
LGVN Longeveron	20	14.93 million	13.26 million	Not Optionable
LMDX LumiraDx	1,210	318.55 million	205.75 million	Not Optionable
OVID Ovid Therapeutics	60	71.11 million	61.80 million	Optionable
RNXT RenovoRx	6	36.57 million	33.23 million	Not Optionable

LMDX, RNXT, LGVN, and OVID Headlines

Recent News About These Companies

Insider Buying: RenovoRx, Inc. (NASDAQ:RNXT) Insider Buys 21,000 Shares of Stock

June 10, 2025 | insidertrades.com

Insider Buying: RenovoRx, Inc. (NASDAQ:RNXT) Insider Acquires 21,000 Shares of Stock

June 9, 2025 | marketbeat.com

RenovoRx (NASDAQ:RNXT) Stock Rating Upgraded by Wall Street Zen

June 6, 2025 | marketbeat.com

RenovoRx (RNXT) PT Raised to $11.50 by Ascendiant on Strong Q1 2025 Results

June 6, 2025 | finance.yahoo.com

RenovoRx (NASDAQ:RNXT) Given New $11.50 Price Target at Ascendiant Capital Markets

June 5, 2025 | marketbeat.com

Ascendiant Capital relève l’objectif de cours de l’action RenovoRx à 11,50€

June 5, 2025 | fr.investing.com

Earnings call transcript: RenovoRx Q1 2025 revenue exceeds expectations

May 17, 2025 | investing.com

RenovoRx, Inc. (NASDAQ:RNXT) Q1 2025 Earnings Call Transcript

May 17, 2025 | msn.com

RenovoRx Inc (RNXT) Q1 2025 Earnings Call Highlights: Promising Revenue Growth and Clinical ...

May 16, 2025 | finance.yahoo.com

Le BPA de RenovoRx a dépassé les attentes, le CA en dessous des prévisions

May 15, 2025 | fr.investing.com

Transcription des résultats : le chiffre d’affaires de RenovoRx au T1 2025 dépasse les attentes

May 15, 2025 | fr.investing.com

RenovoRx, Inc. (RNXT) Q1 2025 Earnings Conference Call Transcript

May 15, 2025 | seekingalpha.com

RenovoRx, Inc. (RNXT) Reports Q1 Loss, Lags Revenue Estimates

May 15, 2025 | zacks.com

RenovoRx Reports First Quarter 2025 Financial Results and Business Highlights

May 15, 2025 | businesswire.com

Earnings Preview For RenovoRx

May 14, 2025 | benzinga.com

RenovoRx to Participate in Fireside Chat at A.G.P. Virtual Healthcare Company Showcase on May 21st

May 14, 2025 | finance.yahoo.com

U.S. Patent Office Issues New Patent to RenovoRx for Novel Trans-Arterial Micro-Profusion (TAMP™) Therapy Platform

May 6, 2025 | finance.yahoo.com

Johns Hopkins Medicine lance le recrutement de patients pour l'essai clinique de phase III TIGeR-PaC en cours de RenovoRx

April 30, 2025 | zonebourse.comZ

Johns Hopkins Medicine lance le recrutement de patients pour l'essai clinique de phase III en cours de Renovorx sur le Tiger-Pac

April 29, 2025 | zonebourse.comZ

Johns Hopkins rejoint l’essai TIGeR-PaC de RenovoRx sur le cancer du pancréas

April 29, 2025 | fr.investing.com

Johns Hopkins Medicine Initiates Patient Enrollment for RenovoRx’s Ongoing Phase III TIGeR-PaC Clinical Trial

April 29, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LMDX, RNXT, LGVN, and OVID Company Descriptions

Longeveron NASDAQ:LGVN

$1.32 +0.02 (+1.54%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.39 +0.07 (+5.30%)

As of 04:05 AM Eastern

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.

LumiraDx NASDAQ:LMDX

LumiraDx Limited operates as a point of care diagnostics company. The company focuses on transforming community-based healthcare by providing critical diagnostic information to healthcare providers. It manufactures and commercializes a diagnostic platform that supports various tests with lab comparable performance at the point of care. The company has tests on the market and in development covering infectious diseases, cardiovascular diseases, diabetes, and coagulation disorders, as well as a portfolio of COVID-19 testing solutions. Its diagnostic testing solutions are deployed by governments and healthcare institutions across laboratories, urgent care, physician offices, pharmacies, schools, and workplaces to screen, diagnose, and monitor wellness, as well as disease. The company is headquartered in London, the United Kingdom.

Ovid Therapeutics NASDAQ:OVID

$0.30 -0.04 (-11.95%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$0.34 +0.04 (+12.58%)

As of 05:31 AM Eastern

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.

RenovoRx NASDAQ:RNXT

$1.28 -0.07 (-5.19%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$1.32 +0.03 (+2.73%)

As of 04:00 AM Eastern

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing proprietary targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is RenovoGem, an oncology drug-device combination product, consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. The company has a research collaboration with Imugene Limited to deliver oncolytic virus therapy for the treatment of difficult-to-access tumors. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time